Alzheimer's: Largest Gene Study Finds 48 New Risk Regions
A Nature study of over 2.7 million people found 118 common gene regions tied to Alzheimer's risk, 48 of them new. It points to drug targets, not a treatment.
Cure Checker Newsroom
In short: Every day we look through all the conditions and diseases on Cure Checker for new studies, approvals and trial news, then write up the most important update in plain language, with sources.
Cystic Fibrosis: Home Monitoring Trial Misses Main Goal
In the conneCT CF trial, home monitoring and coaching raised use of inhaled treatments in cystic fibrosis, but did not delay the first lung flare-up.
Crohn's Disease: Skyrizi Injected Starter Doses in AFFIRM Phase 3
Full Phase 3 AFFIRM data: injected risankizumab starter doses beat placebo at week 12 in Crohn's disease. An FDA decision on the injected start is pending.
Pancreatic Cancer: EU Regulator Panel Backs Daraxonrasib
The EMA's CHMP recommended approval of daraxonrasib (Rasonque) for previously treated metastatic pancreatic cancer. The final EU decision is still pending.
IPF: Admilparant Meets Main Goal in Phase 3 Trial, Company Says
BMS says admilparant beat placebo on lung capacity in the Phase 3 ALOFT-IPF trial at 60 mg. What is known, what is not yet public, and what is next.
Duchenne Exon 44 Drug Del-zota: Phase 1/2 Results Published
Del-zota raised dystrophin about 25% in a small Lancet Neurology trial for exon 44 Duchenne. No movement benefit shown yet; not approved.
HIV Injections Every 8 Weeks Matched Daily Pills in an African Trial
The IMPALA trial (NEJM, Oct 15, 2026): cabotegravir plus rilpivirine shots every 8 weeks kept HIV suppressed in 91.0% vs 89.2% on pills. Not a cure.
Huntington's: SOM3355 Misses Main Goal in Phase 2b Chorea Trial
A Phase 2b trial of SOM3355 for Huntington's chorea missed its main goal. A planned subgroup analysis was positive, and a Phase 3 trial is planned.
Parkinson's: Solengepras Cuts "Off" Time in Phase 3 Trial
A once-daily pill that does not act on dopamine met its main goal in a Phase 3 Parkinson's trial, cutting daily "off" time by 0.61 hours more than placebo.
HIV: Two-Drug Doravirine and Raltegravir Switch Held Up in Phase 2
In the DORAL phase 2 trial of 114 adults with HIV, switching to once-daily doravirine plus raltegravir kept the virus suppressed, with one rebound.
Neuroblastoma: Removing Most of the Tumor Linked to Better Survival
Children with high-risk neuroblastoma whose surgeons removed 90% or more of the main tumor had better 5-year survival in a look-back study of 326.
Prader-Willi: Testosterone in Young Men Had Minor Effects on Behavior
A Dutch study of 59 young males with Prader-Willi syndrome found testosterone did not significantly change behavior scores. It had no placebo group.
Duchenne: Deramiocel Two-Year Extension Data, Company-Reported
Capricor reported two-year HOPE-3 extension data for deramiocel in Duchenne. The results are company-reported and not significance-tested. FDA decision Nov 22.
FTD and ALS: $26 Million NIH Study of C9orf72 Carriers Planned
A $26M NIH-funded Penn-led study will follow 330 C9orf72 carriers to find early signs of FTD and ALS. Enrollment starts in December. Not a treatment trial.
Pancreatic Cancer: First Patients Treated in RASolute 309 Phase 3
Revolution Medicines began treating patients in RASolute 309, a Phase 3 trial of daraxonrasib plus zoldonrasib as first treatment for RAS G12D pancreatic cancer
COPD: Tozorakimab Cut Flare-Ups in Two Phase 3 Trials
Tozorakimab cut COPD flare-ups by 29% and 34% in former smokers in two Phase 3 trials of 2,306 adults. What was reported and what comes next.
Crohn's Disease: Guselkumab Five-Year GALAXI 1 Results
Five-year GALAXI 1 data on guselkumab (Tremfya) in Crohn's disease: 97.7% of those still on it were in remission, but 46.0% of all who started.
FDA Approves Bixlenvo, a Daily HIV Pill for Suppressed Adults
The FDA approved Bixlenvo on August 27, 2026, a once-daily pill that manages HIV in adults whose virus is already suppressed. It is not a cure.
Litifilimab for Skin Lupus: 52-Week Phase 2 Data Reported
Biogen reported 52-week Phase 2 data for litifilimab in cutaneous (skin) lupus: 27.2% reached clear or almost clear skin. Company-reported, not a cure.
MS Stem-Cell Transplant: Blood Markers Stay Low for Years
In 24 people with severe MS, inflammation markers stayed low for up to 5 years after a stem-cell transplant (aHSCT). What it shows and what it does not.
Osteosarcoma: OST-HER2 Reports 71.2% Three-Year Survival
OS Therapies reports 71.2% three-year survival with OST-HER2 in lung-spread osteosarcoma, versus 45.8% in historical controls. Early, not randomized.
Pancreatic Cancer: VCN-01 Virus Therapy Phase 2b Results
VIRAGE, a Phase 2b trial in 112 people with metastatic pancreatic cancer, reported better survival when VCN-01 was added to chemo. What it shows.
Rexaceract in Parkinson's: Small Phase 1b Extension Shows Promise
Gain Therapeutics reports stable motor scores over 12 months in a small, open-label Phase 1b extension of rexaceract for Parkinson's disease.
SMA: FDA Approves Isembyld, a Muscle-Targeted Medicine
The FDA approved Isembyld (apitegromab) on Sept 11, 2026 for SMA in people 2 and older already on SMN2 treatment. Trial results and the fracture warning.
FDA Approves Finerenone for Kidney Disease in Type 1 Diabetes
On Sept 17, 2026 the FDA approved finerenone (Kerendia) for kidney disease in adults with type 1 diabetes. It does not treat diabetes itself.
Ulefnersen Wins a Phase 3 Trial in FUS-ALS: What the Results Mean
Ulefnersen met its main goal in the Phase 3 FUSION trial for FUS-ALS (p = 0.0005). What was tested, what was reported, and what happens next.